Boundless Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference

Boundless Bio, a clinical-stage oncology company trading on Nasdaq under the ticker BOLD, has announced its participation in the Piper Sandler 37th Annual Healthcare Conference. The fireside chat, featuring President and CEO Zachary Hornby, will take place on December 3, 2025, at 9:30 a.m. ET in New York City. Investors and interested parties can access a live and archived webcast of the discussion on Boundless Bio’s official website under the “Events & Presentations” section.

Founded with a mission to revolutionize cancer therapies, Boundless Bio is focusing on the biology of extrachromosomal DNA (ecDNA), a factor linked to oncogene amplification in approximately 14% to 17% of cancer patients. This groundbreaking approach addresses the urgent need for effective treatments in patients suffering from oncogene amplified tumors.

The company is developing innovative ecDNA-directed therapeutic candidates (ecDTx), including BBI-355 and BBI-825. BBI-355 is an oral, selective inhibitor of checkpoint kinase 1 (CHK1), while BBI-825 is an oral, selective inhibitor of ribonucleotide reductase (RNR). Both are currently undergoing evaluation in the Phase 1/2 POTENTIATE clinical trial for oncogene amplified cancers.

Additionally, Boundless Bio is advancing projects involving another ecDNA therapeutic candidate, BBI-940, which is expected to be a first-in-class orally bioavailable, selective Kinesin degrader. Headquartered in San Diego, California, Boundless Bio is on the forefront of developing transformative treatments for patients with previously challenging cancers.

For more details about Boundless Bio’s initiatives and to stay updated on company news, interested parties are encouraged to visit their official website or follow them on LinkedIn and X (formerly Twitter).

Investors should closely monitor Boundless Bio (Nasdaq: BOLD) as the company prepares for its participation in the upcoming Piper Sandler 37th Annual Healthcare Conference. Zachary Hornby, the CEO, will discuss the company’s innovative research and strategic direction, which may provide deeper insights into its clinical progress and market positioning.

Boundless Bio is at the forefront of cancer therapy innovation, focusing on extrachromosomal DNA (ecDNA) to treat oncogene amplified tumors, an area representing a critical unmet need in oncology. Their lead drug candidates, BBI-355 and BBI-825, are poised to potentially alter the treatment landscape, especially for patients who have limited options due to the aggressive nature of their tumors. The ongoing phase 1/2 POTENTIATE clinical trial will be pivotal in shaping investor sentiment as results emerge.

Market trends indicate a growing interest in targeted cancer therapies, especially those that address specific genetic abnormalities. Given that 14% to 17% of cancer patients possess oncogene amplified tumors, Boundless Bio operates in a lucrative niche that could see increasing urgency and funding, especially as new data emerges.

Investors should focus on the key takeaways from Hornby’s presentation, especially regarding timelines for clinical trials and the potential market impact of the findings. The company’s ongoing IND-enabling studies for BBI-940, a potentially first-in-class agent, signify its commitment to expanding its pipeline, which could attract additional investment and partnership opportunities in the future.

In summary, Boundless Bio represents a compelling investment opportunity in the oncology sector for those looking to capitalize on breakthroughs in cancer treatment. Keeping an eye on the developments from the Piper Sandler conference might provide investors with critical insights to inform their strategies.